The end-of-dose phenomenon in Parkinson’s refers to the fact that patients with Parkinson’s disease may experience a decrease in drug efficacy and a shortening of the effective duration of action after taking the drug for a period of time, and the patient’s symptoms may fluctuate regularly with the concentration of the drug in the blood. In this case, improvement can be achieved by increasing the number of daily doses, or by increasing the dose of each dose, or by switching to an extended-release agent, or by adding a dopamine receptor agonist. The end-of-dose phenomenon of Parkinson’s is not easily recognized by patients clinically, and physicians have no way to directly observe it. This condition is a relatively common complication of Parkinson’s treatment, and levodopa treatment is recommended, and levodopa dosing should be adjusted for this phenomenon, and levodopa extended-release agents are recommended, as well as early interventions that can be given to patients to be able to improve long-term function.